Compare Stitch Fix Inc (SFIX) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

Stitch Fix (SFIX) trades at $2.45, down 9.26% in the last session, reflecting negative sentiment following its Q4 2026 results and weak fiscal 2027 guidance. The stock exhibits a bearish technical trend, with key support at $2. Fundamentally, while revenue stabilized near $1.3B and net losses narrowed significantly to -$29M in FY2025, the company remains unprofitable with a negative net margin. Recent news highlights multiple law firm investigations and a post-earnings stock plunge due to cautious outlook.

The outlook is cautious. A low P/S ratio of 0.24 may attract value seekers, but persistent losses, negative cash flow, and declining active client projections pose substantial risks. Analyst consensus is mixed with a $3.40 price target, but the high proportion of Hold ratings (69.7%) signals skepticism about near-term recovery, emphasizing execution and demand challenges.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.